Stuart Therapeutics Announces Exclusive Worldwide License Agreement With Glaukos Corporation; Under Agreement, Glaukos Will Assume All Costs For Development Of ST-113
Portfolio Pulse from Benzinga Newsdesk
Stuart Therapeutics has entered into an exclusive worldwide license agreement with Glaukos Corporation. Under the agreement, Glaukos will assume all costs for the development of ST-113.
October 18, 2023 | 7:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Glaukos Corporation has entered into a licensing agreement with Stuart Therapeutics and will bear all costs for the development of ST-113.
The news is directly related to Glaukos Corporation as they have entered into a licensing agreement with Stuart Therapeutics. The financial impact on Glaukos is neutral in the short term as the costs for the development of ST-113 could lead to potential long-term gains if the product is successful. However, it also represents a financial risk as they are bearing all development costs.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100